Estimated market cap $626.97MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Nov 6, 2026, last close Nov 13, 2026.153.29M shares, shares as of Nov 6, 2026CIK 1447028The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
—
No open-market trades
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Arbutus Biopharma Corporation's latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Arbutus Biopharma Corporation and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
138
49.1% of shares · 43 added
Latest 10-Q
Q3 2026
What changed in Arbutus Biopharma Corporation's latest quarterly report, compared with the one before.
Filed Nov 10, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Feb 4, 2025. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
138 funds report ABUS. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 71% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 140.61M reported shares by 197.85M shares, from the company’s SEC filing as of Aug 10, 2026.
177 funds hold the stock.
Q3 2026: 49% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202562%
Q3 202562%
Q4 202563%
Q1 202671%
Q2 202671%
Q3 2026 (so far)49%
Q3 2026. 39 new, 43 added to, 29 trimmed, 80 exited since Q2 2026.
Download CSVEvery fund that holds ABUS, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Arbutus Biopharma Corporation and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2015
1
—
207,417
$2.5M
Q3 2015
55
+54
34.85M
$212.3M
Q4 2015
51
-4
18.37M
$81.7M
Q1 2016
49
-2
17.71M
$73.1M
Q2 2016
51
+2
17.55M
$61.1M
Q3 2016
48
-3
33.44M
$115.0M
Q4 2016
55
+7
36.47M
$89.5M
Q1 2017
53
-2
36.62M
$119.0M
Q2 2017
50
-3
36.89M
$132.8M
Q3 2017
53
+3
33.02M
$207.1M
Q4 2017
51
-2
34.21M
$172.8M
Q1 2018
50
-1
18.38M
$91.9M
Q2 2018
71
+21
22.33M
$158.9M
Q3 2018
88
+17
24.31M
$230.1M
Q4 2018
71
-17
24.41M
$93.5M
Q1 2019
72
+1
24.11M
$86.5M
Q2 2019
62
-10
21.19M
$44.1M
Q3 2019
55
-7
19.47M
$29.7M
Q4 2019
59
+4
24.39M
$67.8M
Q1 2020
48
-11
26.29M
$26.5M
Q2 2020
51
+3
26.12M
$47.6M
Q3 2020
65
+14
24.14M
$75.5M
Q4 2020
80
+15
23.42M
$83.4M
Q1 2021
94
+14
26.02M
$86.5M
Q2 2021
91
-3
28.91M
$87.6M
Q3 2021
100
+9
34.90M
$149.8M
Q4 2021
123
+23
40.49M
$157.5M
Q1 2022
119
-4
43.90M
$130.6M
Q2 2022
113
-6
44.31M
$120.0M
Q3 2022
127
+14
46.63M
$89.2M
Q4 2022
114
-13
54.22M
$126.4M
Q1 2023
122
+8
65.29M
$197.8M
Q2 2023
111
-11
66.24M
$152.4M
Q3 2023
99
-12
74.99M
$152.2M
Q4 2023
112
+13
86.05M
$215.1M
Q1 2024
119
+7
101.16M
$261.0M
Q2 2024
131
+12
96.80M
$298.7M
Q3 2024
144
+13
101.19M
$389.6M
Q4 2024
153
+9
104.09M
$340.4M
Q1 2025
168
+15
111.84M
$390.3M
Q2 2025
163
-5
118.40M
$365.9M
Q3 2025
167
+4
118.30M
$537.0M
Q4 2025
172
+5
122.03M
$586.9M
Q1 2026
167
-5
139.11M
$626.0M
Q2 2026
177
+10
140.61M
$674.9M
Q3 2026
138
-39
75.29M
$359.6M
Each point is a quarter-end, from Q2 2015 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (03879J100). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2015) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.